Pelage Pharmaceuticals Closes $120M Series B Led by ARCH Venture Partners and GV

Deal Summary

Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotech based in Los Angeles, closed a $120M Series B financing co‑led by ARCH Venture Partners and GV, with participation from Main Street Advisors, Visionary Ventures and YK Bioventures. The company will use the funds to advance its clinical programs.